Jean Gerald Nougaisse, PA-C | |
3400 Mcclure Bridge Rd Bldg B, Duluth, GA 30096-6675 | |
(678) 957-8801 | |
(678) 957-8804 |
Full Name | Jean Gerald Nougaisse |
---|---|
Gender | Male |
Speciality | Orthopaedic Surgery |
Location | 3400 Mcclure Bridge Rd Bldg B, Duluth, Georgia |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1164486817 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
363AS0400X | Physician Assistant - Surgical | 005668 (New York) | Secondary |
207X00000X | Orthopaedic Surgery | 004761 (Georgia) | Primary |
Mailing Address | Practice Location Address |
---|---|
Jean Gerald Nougaisse, PA-C 2512 Kelman Pl, Dacula, GA 30019-7099 Ph: (770) 277-2424 | Jean Gerald Nougaisse, PA-C 3400 Mcclure Bridge Rd Bldg B, Duluth, GA 30096-6675 Ph: (678) 957-8801 |
News Archive
Celgene Corporation today announced the successful pricing of three series of senior unsecured notes for an aggregate principal amount of $1.25 billion.
An assay that identifies a peculiar but important abnormality in cancer cells has been developed and validated by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
Transgenomic, Inc. today reported financial results for the three and nine months ended September 30, 2011 and provided a business update.
Patients who have a clot in their legs and are considering whether to be treated with traditional blood-thinning medication or undergo a minimally-invasive catheter-based clot removal procedure should feel comfortable that there is no difference in death rates between the two treatments, although there are more bleeding risks with the catheter procedure, according to a study by Temple University School of Medicine researchers.
Abbott and World Health Organization (WHO) Director-General, Margaret Chan, have agreed on a balanced approach to provide Kaletra/Aluvia (lopinavir/ritonavir) capsules and tablets to more patients in the developing world, while supporting continued long-term biopharmaceutical research and development.
› Verified 2 days ago